retatrutide type 2 diabetes phase 2 weight loss 2024 ESC 2024: improves lipid and cardiovascular risk profile in II trial Retatrutide, an experimental weight-loss drug,
Description
doi: 10.1021/jf901660g, PMID: [DOI] [PubMed] [Google Scholar] 13
Furthermore, semaglutide treatment led to an increase in mitochondrial content and density, as well as an increase in maximal mitochondrial respiration
References National Academies Press (US)
Liraglutide was found to improve bone microarchitecture and reverse bone loss in rats with diabetic osteoporosis
Embrace healthy fats : Not all fats are created equal
